According to the latest report by IMARC Group, titled “Hydroxychloroquine Market Size: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026″, the global hydroxychloroquine market size exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026.
Hydroxychloroquine (HCQ) is a derivative of chloroquine that is primarily used to treat or prevent malaria. It is also used in the treatment of numerous autoimmune diseases, such as systemic and discoid lupus erythematosus and rheumatoid arthritis. It exhibits endothelial stabilizing and anti-thrombotic effects as it containsantigens and cytokines.
Request Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample
Market Trends
The global market is majorly driven by the outbreak of the COVID-19 pandemic across the globe. Hydroxychloroquine has gained widespread prominence due to its effectiveness in the treatment of COVID-19 patients, thereby providing an impetus to the market growth. Furthermore, the increasing prevalence of malaria and other chronic disorders is providing a thrust to the market growth. Along with this, the rapidly rising cases of autoimmune diseases, and the escalating demand for generic drugs are further providing an impetus to the market growth. Other factors, including increasing investments by the governments of several countries to improve the overall healthcare infrastructure and extensive research and development (RD) activities, are also projected to drive market growth.
Our report has categorized the market based on dosage type, distribution, application, grade and route of administration.
Breakup by Dosage Type:
200 Mg
300 Mg
400 Mg
Others
Breakup by Distribution:
Hospital Pharmacies
Retail Pharmacies
Others
Breakup by Application:
Rheumatoid Arthritis
Lupus Erythematosus
Malaria
Coronavirus (COVID-19)
Others
Breakup by Grade:
USP Standards Grade
EP Standards Grade
Pharmaceutical Standards Grade
Others
Breakup by Route of Administration:
Oral
Intravenous
Breakup by Region:
North America: (United States, Canada)
Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa
Competitive Landscape Key Player:
Amneal Pharmaceuticals Inc.Cardinal Health Inc.Cipla Ltd.Ipca Laboratories Ltd.Laurus LabsLupin LimitedMylan N.V.Novartis AGPrasco LaboratoriesReddy’s Laboratories Ltd.Sanofi S.A.Teva Pharmaceutical Industries Ltd.Torrent PharmaZydus Cadila
Explore Full Report with TOC List of Figure: https://www.imarcgroup.com/hydroxychloroquine-market
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800 |
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
